Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, 14-week Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Multisite Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Next Previous
X
Search
Trial Profile

A Phase 2, 14-week Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Multisite Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclobenzaprine (Primary)
  • Indications Pain; Post acute COVID 19 syndrome
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms PREVAIL
  • Sponsors Tonix Pharmaceuticals Holding Corp

    • Most Recent Events

    • 22 May 2024 According to a Tonix Pharmaceuticals Holding Corp media release, data from this study will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held May 28-31, 2024 at the Loews Miami Beach Hotel in Miami Beach, Fla.
    • 12 Oct 2023 According to a Tonix Pharmaceuticals Holding Corp media release, enrollment in a Phase 2 proof-of-concept study has been completed, and topline results were reported in the third quarter of 2023.
    • 05 Sep 2023 According to a Tonix Pharmaceuticals Holding Corp media release, the company expect to present full data in a peer-reviewed format and at upcoming medical conferences.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top